[1] |
STANKOVIC M N, MLADENOVIC D R, DURICIC I, et al. Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease[J]. Arch Med Res, 2014, 45(2):116-124.
|
[2] |
WILLIAMSON R M, PRICE J F, GLANCY S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes:the edinburgh type 2 diabetes study[J]. Diabetes Care, 2011, 34(5):1139-1144.
|
[3] |
PATEL V B, CLARKE N, WANG Z C, et al. Angiotensin Ⅱ induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17:a positive feedback mechanism in the RAS[J]. J Mol Cell Cardiol, 2014, 66:167-176.
|
[4] |
SANTOS R A S, SAMPAIO W O, ALZAMORA A C, et al. The ace2/angiotensin-(1-7)/Mas axis of the renin-angiotensin system:focus on angiotensin-(1-7)[J]. Physiol Rev, 2018, 98(1):505-553.
|
[5] |
DE MACÊDO S M, GUIMARÃES T A, FELTENBERGER J D, et al. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases[J]. Peptides, 2014, 62:189-196.
|
[6] |
SIMÕES E SILVA A C, SILVEIRA K D, FERREIRA A J, et al. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis[J]. Br J Pharmacol, 2013, 169(3):477-492.
|
[7] |
VERGNIOL J, BARBU V, LEMOINE M, et al. 873 progression of NAFLD in humans is associated with the activation of the renin-angiotensin system[J]. J Hepatol, 2011, 54(S1):S348.
|
[8] |
汪亮. 肾素-血管紧张素系统在非酒精性脂肪肝发病中的作用[J]. 重庆医学, 2010, 39(22):3139-3141, 3149.
|
|
WANG L. The role of renin-angiotensin system in the pathogenesis of nonalcoholic fatty liver disease[J]. Chongqing Medicine, 2010, 39(22):3139-3141, 3149. (in Chinese)
|
[9] |
LIU B, WU R, ZHANG W, et al. Fosinopril improves liver fibrosis by upregulating ACE2/Angiotensin-(1-7) axis activation in rats with nonalcoholic steatohepatitis[J]. Lat Am J Pharm, 2012, 31(4):588-596.
|
[10] |
CAO X, YANG F Y, SHI T T, et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis activates Akt signaling to ameliorate hepatic steatosis[J]. Sci Rep, 2016, 6:21592.
|
[11] |
CENGIZ M, OZENIRLER S, YILMAZ G, et al. Impact of hepatic immunoreactivity of angiotensin-converting enzyme 2 on liver fibrosis due to non-alcoholic steatohepatitis[J]. Clin Res Hepatol Gastroenterol, 2015, 39(6):692-698.
|
[12] |
WANG K, LIU X Q, XIAO H, et al. The correlation between inflammatory injury induced by LPS and RAS in EpH4-Ev cells[J]. Int Immunopharmacol, 2017, 46:23-30.
|
[13] |
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版)[J]. 传染病信息, 2018, 31(5):393-402, 420.
|
|
Fatty Liver and Alcoholic Liver Disease Group, Society of Hepatology, Chinese Medical Association, Chinese Medical Association Fatty Liver Disease Expert Committee. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:a 2018 update[J]. Infectious Disease Information, 2018, 31(5):393-402, 420. (in Chinese)
|
[14] |
DAY C P, JAMES O F W. Steatohepatitis:a tale of two "hits"?[J]. Gastroenterology, 1998, 114(4):842-845.
|
[15] |
SANTOS R A S, SIMOES E SILVA A C, MARIC C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas[J]. Proc Natl Acad Sci U S A, 2003, 100(14):8258-8263.
|
[16] |
YAN Z G, FAN R F, YIN S J, et al. Protective effects of Ginkgo biloba leaf polysaccharide on nonalcoholic fatty liver disease and its mechanisms[J]. Int J Biol Macromol, 2015, 80:573-580.
|
[17] |
WU Y, MA K L, ZHANG Y, et al. Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease[J]. Liver Int, 2016, 36(10):1525-1534.
|
[18] |
SANTOS S H S, ANDRADE J M O, FERNANDES L R, et al. Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-κB in rats fed with high-fat diet[J]. Peptides, 2013, 46:47-52.
|
[19] |
CAO X, SONG L N, ZHANG Y C, et al. Angiotensin-converting enzyme 2 inhibits endoplasmic reticulum stress-associated pathway to preserve nonalcoholic fatty liver disease[J]. Diabetes Metab Res Rev, 2019, 35(4):e3123.
|
[20] |
霍苗苗, 程变巧,林伟国,等. 扶正化瘀方对非酒精性脂肪性肝病大鼠肝纤维化及ACE-Ang Ⅱ-AT1R轴的影响[J]. 解放军医学杂志, 2018, 43(2):114-119.
|
|
HUO M M, CHENG B Q, LIN W G, et al. Therapeutic effects of Fuzhenghuayu decoction on nonalcoholic steatohepatic fibrosis rats by regulating ACE-AngⅡ-AT1R axis[J]. Medical Journal of Chinese People's Liberation Army, 2018, 43(2):114-119. (in Chinese)
|
[21] |
刘颖,王凯,纪晓霞,等. 肾素血管紧张素系统(RAS)两条轴相互负向调节与大鼠非酒精性脂肪肝病(NAFLD)肝损伤的关系研究[J]. 畜牧与兽医, 2019, 51(5):48-54.
|
|
LIU Y, WANG K, JI X X, et al. Relationship between negative reversal of two axes of renin angiotensin (RAS) and liver injury induced by non-alcoholic fatty liver disease (NAFLD) in rats[J]. Animal Husbandry & Veterinary Medicine, 2019, 51(5):48-54. (in Chinese)
|